Log in
Enquire now
‌

US Patent 10306874 Non-human animals having a humanized lymphocyte-activation gene 3

Patent 10306874 was granted and assigned to Regeneron Pharmaceuticals on June, 2019 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
Current Assignee
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10306874
Date of Patent
June 4, 2019
Patent Application Number
15355392
Date Filed
November 18, 2016
Patent Citations Received
‌
US Patent 10925264 Genetically modified non-human animal with human or chimeric LAG-3
‌
US Patent 11564381 Genetically modified non-human animal with human or chimeric LAG3
Patent Primary Examiner
‌
Shin-Lin Chen
Patent abstract

Non-human animals, and methods and compositions for making and using the same, are provided, wherein the non-human animals comprise a humanization of a Lymphocyte activation gene 3 (Lag3). The non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous Lag3 locus so that the non-human animals express a Lag3 polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10306874 Non-human animals having a humanized lymphocyte-activation gene 3

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.